1. Kolodziej M, Klein I, Reisman L (2013) A new value proposition. Nat Med 19:1365. https://doi.org/10.1038/nm1113-1365
2. Temple RJ (1995) A regulatory authority’s opinion about surrogate endpoints. In: Nimmo W, Tucker G (eds) Clinical measurement in drug evaluation. Wiley, New York
3. Department of Health and Human Services, Food and Drug Administration (1992) New drug, antibiotic, and biological drug product regulations: accelerated approval. Fed Regist 57:13234–13242
4. D’Agostino RB (2000) Debate: the slippery slope of surrogate outcomes. Curr Control Trials Cardiovas Med 1:76–78
5. Svensson S, Menkes DB, Lexchin J (2013) Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 173:611–612